Catalyst Pharmaceuticals, Inc. plans are underway to seek approval from the FDA to increase the approved FIRDAPSE maximum daily dosage from 80mg to 100mg.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.14 USD | +1.03% | +0.43% | -10.08% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.08% | 1.77B | |
-2.47% | 88.14B | |
+3.29% | 40.44B | |
-15.39% | 32.24B | |
+51.96% | 24.39B | |
-14.05% | 15.59B | |
-39.65% | 12.3B | |
-6.52% | 12.18B | |
-13.66% | 12.14B | |
+5.17% | 8.87B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Plans Are Underway to Seek Approval from the FDA to Increase the Approved FIRDAPSE